• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

暴露后狂犬病疫苗接种者中中和抗体的影响因素及预测

Influencing factors and prediction of neutralizing antibodies in post-exposure rabies vaccine recipients.

作者信息

Huang Chunping, Zhang Ling, Shan Xiaoyue, Tan Siwei, Ye Haipeng, Cao Chengjian, Zhang Lei

机构信息

Hangzhou Center for Disease Control and Prevention (Hangzhou Health Supervision Institution), Hangzhou, China.

Hangzhou Hospital for the Prevention and Treatment of Occupational Disease, Hangzhou, China.

出版信息

Heliyon. 2024 Aug 6;10(15):e35673. doi: 10.1016/j.heliyon.2024.e35673. eCollection 2024 Aug 15.

DOI:10.1016/j.heliyon.2024.e35673
PMID:39170215
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11336818/
Abstract

To assess the factors that influencing the persistence of virus neutralizing antibody (VNA), and to establish prediction models to provide the appropriate timing for booster administration, a cohort of post-exposure rabies vaccine recipients was investigated. The VNA determined records from 2019 to 2023 and interrelated factors were analyzed, including gender, age, rabies immunoglobulin (RIG) administration, vaccine products, vaccination schedule, and vaccination intervals etc. The geometric mean of VNA titre within 1 month after primary vaccination with 2-1-1 schedule was statistically higher than that with 5-dose course ( = 0.031). The interaction between exposure and vaccination schedule was observed on primary vaccination, which showed that a decrease of 19.74 % (95 % CI: 5.99%-64.95 %,  = 0.008) of VNA titre among vaccinee with 5-dose and exposure III. Individuals with RIG administration produced lower VNA titres than those without RIG administration ( = 0.001). Vaccine products (Chengda,  = 0.015; human diploid cell,  = 0.026) and re-exposed time ( = 0.000) exhibited independent effects following booster vaccination. Based on the prediction model, the 99 % individual prediction intervals (IPI) of VNA titres were established at 3, 6, 12 and 18 months for the 12 characteristic populations respectively. The cases of VNA below 0.5 IU/ml first appeared at 6 months in group D of primary vaccinations and at 10 years in group F of boosters. We conclude that for primary vaccination 2-1-1 schedule is more efficient than 5-dose; the use of residual rabies immunoglobulin for distal intramuscular injection isn't recommended. The 99 % IPI of VNA titres could provide the appropriate timing for booster vaccination.

摘要

为评估影响病毒中和抗体(VNA)持久性的因素,并建立预测模型以确定加强免疫接种的合适时机,对一组暴露后狂犬病疫苗接种者进行了调查。分析了2019年至2023年期间测定的VNA记录及相关因素,包括性别、年龄、狂犬病免疫球蛋白(RIG)接种情况、疫苗产品、接种程序和接种间隔等。采用2-1-1程序进行初次接种后1个月内VNA滴度的几何平均值在统计学上高于5针法程序(P = 0.031)。初次接种时观察到暴露与接种程序之间存在交互作用,结果显示,5针法程序且暴露于III级的接种者VNA滴度降低了19.74%(95%CI:5.99%-64.95%,P = 0.008)。接种RIG的个体产生的VNA滴度低于未接种RIG的个体(P = 0.001)。加强免疫接种后,疫苗产品(成大,P = 0.015;人二倍体细胞,P = 0.026)和再次暴露时间(P = 0.000)显示出独立影响。基于预测模型,分别为12个特征人群建立了3、6、12和18个月时VNA滴度的99%个体预测区间(IPI)。VNA低于0.5 IU/ml的情况首次出现在初次接种D组的6个月时和加强免疫F组的10年时。我们得出结论,对于初次接种,2-1-1程序比5针法更有效;不建议将剩余的狂犬病免疫球蛋白用于远端肌肉注射。VNA滴度的99% IPI可为加强免疫接种提供合适的时机。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ca1/11336818/5b6bd4099015/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ca1/11336818/054759143302/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ca1/11336818/5b6bd4099015/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ca1/11336818/054759143302/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ca1/11336818/5b6bd4099015/gr2.jpg

相似文献

1
Influencing factors and prediction of neutralizing antibodies in post-exposure rabies vaccine recipients.暴露后狂犬病疫苗接种者中中和抗体的影响因素及预测
Heliyon. 2024 Aug 6;10(15):e35673. doi: 10.1016/j.heliyon.2024.e35673. eCollection 2024 Aug 15.
2
Rabies pre-exposure prophylaxis elicits long-lasting immunity in humans.狂犬病暴露前预防可在人类中引发持久免疫力。
Vaccine. 2016 Nov 21;34(48):5959-5967. doi: 10.1016/j.vaccine.2016.09.058. Epub 2016 Oct 27.
3
Efficacy of rabies vaccines in dogs and cats and protection in a mouse model against European bat lyssavirus type 2.狂犬病疫苗对犬猫的效力及在小鼠模型中对欧洲2型蝙蝠狂犬病病毒的防护作用
Acta Vet Scand. 2017 Oct 2;59(1):64. doi: 10.1186/s13028-017-0332-x.
4
[Analysis of determination of rabies virus neutralizing antibody titres in the sera of vaccinated humans.].[接种疫苗人群血清中狂犬病毒中和抗体效价测定的分析。]
Vopr Virusol. 2019;64(6):298-305. doi: 10.36233/0507-4088-2019-64-6-298-305.
5
Immunogenicity and 1-year boostability of a three-dose intramuscular rabies pre-exposure prophylaxis schedule in adults receiving immunosuppressive monotherapy: a prospective single-centre clinical trial.免疫原性和 1 年增强性:成人接受免疫抑制单药治疗时,三种剂量肌内狂犬病暴露前预防方案:一项前瞻性单中心临床试验。
J Travel Med. 2023 Apr 5;30(2). doi: 10.1093/jtm/taac148.
6
Relationship between virus-neutralizing antibody levels and the number of rabies vaccinations: a prospective study of dogs in Japan.病毒中和抗体水平与狂犬病疫苗接种次数的关系:日本犬的前瞻性研究。
Jpn J Infect Dis. 2013;66(1):17-21. doi: 10.7883/yoken.66.17.
7
Evaluation of rabies virus neutralizing antibody titres induced by intramuscular inoculation of rabies DNA vaccine in mice and Bonnet monkeys (Macaca radiata).肌肉注射狂犬病DNA疫苗在小鼠和帽猴(食蟹猴)中诱导产生的狂犬病病毒中和抗体效价评估。
Indian J Exp Biol. 2001 Jun;39(6):533-6.
8
Rabies neutralizing antibody after 2 intradermal doses on days 0 and 21 for pre-exposure prophylaxis.狂犬病中和抗体在第 0 天和第 21 天接受 2 剂皮内剂量用于暴露前预防。
Vaccine. 2013 Mar 25;31(13):1748-51. doi: 10.1016/j.vaccine.2013.01.035. Epub 2013 Jan 29.
9
Early rabies antibody response to intramuscular booster in previously intradermally immunized travelers using human diploid cell rabies vaccine.使用人二倍体细胞狂犬病疫苗进行皮内免疫的旅行者,肌肉注射加强针后的早期狂犬病抗体反应。
J Travel Med. 2001 May-Jun;8(3):122-6. doi: 10.2310/7060.2001.24445.
10
Short duration of neutralizing antibody titers after pre-exposure rabies vaccination with suckling mouse brain vaccine.使用乳鼠脑疫苗进行暴露前狂犬病疫苗接种后,中和抗体滴度持续时间较短。
Braz J Med Biol Res. 1998 Oct;31(10):1275-80. doi: 10.1590/s0100-879x1998001000007.

引用本文的文献

1
One-step ahead: evaluating the efficacy of single-visit rabies pre-exposure prophylaxis against conventional multi-visit protocol: a randomized non-inferiority clinical trial.前瞻性一步研究:评估单次就诊狂犬病暴露前预防方案对比传统多次就诊方案的疗效:一项随机非劣效性临床试验
Trop Dis Travel Med Vaccines. 2025 Aug 7;11(1):25. doi: 10.1186/s40794-025-00262-3.

本文引用的文献

1
Evaluating the benefit of serology during potential Australian bat lyssavirus and rabies post-exposure prophylaxis.评估在潜在的澳大利亚蝙蝠狂犬病毒和狂犬病暴露后预防中血清学的益处。
Aust N Z J Public Health. 2023 Dec;47(6):100091. doi: 10.1016/j.anzjph.2023.100091. Epub 2023 Nov 6.
2
Immune response after rabies pre-exposure prophylaxis and a booster dose in Australian bat carers.狂犬病暴露前预防和加强免疫后澳大利亚蝙蝠护理者的免疫反应。
Zoonoses Public Health. 2023 Sep;70(6):465-472. doi: 10.1111/zph.13048. Epub 2023 May 11.
3
Rabies post-exposure prophylaxis of international travellers - Results from two major German travel clinics.
国际旅行者狂犬病暴露后预防-来自两家德国大型旅行诊所的结果。
Travel Med Infect Dis. 2023 May-Jun;53:102573. doi: 10.1016/j.tmaid.2023.102573. Epub 2023 Apr 20.
4
[Safety and immunogenicity of freeze-dried rabies vaccine (Vero-cells) for human use in healthy people aged 9-65 years].人用冻干人用狂犬病疫苗(Vero细胞)在9至65岁健康人群中的安全性和免疫原性
Zhonghua Yu Fang Yi Xue Za Zhi. 2023 Feb 6;57(2):222-228. doi: 10.3760/cma.j.cn112150-20220314-00235.
5
Evaluation and Correlation of Rabies Vaccine Potency Using the National Institute of Health, Rapid Focus Fluorescent Inhibition, and Passive Hemagglutination Tests.采用美国国立卫生研究院、快速荧光灶抑制试验和被动血凝抑制试验评估和关联狂犬病疫苗效力。
Viral Immunol. 2022 Mar;35(2):159-169. doi: 10.1089/vim.2021.0181. Epub 2022 Feb 1.
6
Delayed rabies post-exposure prophylaxis treatment among Dutch travellers during their stay abroad: a comprehensive analysis.荷兰旅行者在国外逗留期间延迟接种狂犬病暴露后预防治疗:综合分析。
J Travel Med. 2021 Apr 14;28(3). doi: 10.1093/jtm/taaa240.
7
Epidemiology of rabies cases among international travellers, 2013-2019: A retrospective analysis of published reports.2013-2019 年国际旅行者狂犬病病例的流行病学:已发表报告的回顾性分析。
Travel Med Infect Dis. 2020 Jul-Aug;36:101766. doi: 10.1016/j.tmaid.2020.101766. Epub 2020 Jun 7.
8
Rabies exposure in travellers to Asia, the Middle East, Africa, South and Central America-a German Airport study.旅行者在亚洲、中东、非洲、南美和中美感染狂犬病的情况——一项德国机场研究。
J Travel Med. 2020 Nov 9;27(7). doi: 10.1093/jtm/taaa058.
9
[Expert consensus on rabies exposure prophylaxis].[狂犬病暴露预防专家共识]
Zhonghua Yu Fang Yi Xue Za Zhi. 2019 Jul 6;53(7):668-679. doi: 10.3760/cma.j.issn.0253-9624.2019.07.004.
10
Rabies postexposure prophylaxis in international travellers: Results from a Spanish travellers referral unit.国际旅行者的狂犬病暴露后预防:来自西班牙旅行者转诊单位的结果。
Med Clin (Barc). 2020 Jan 24;154(2):55-58. doi: 10.1016/j.medcli.2018.12.015. Epub 2019 Feb 20.